Medtronic (MDT) Stock Forecast & Price Target

Q: What analysts cover Medtronic?

Medtronic has been rated by research analysts at Argus , Barclays , BTIG Research , Citigroup , Deutsche Bank Aktiengesellschaft , Evercore , Jefferies Financial Group , JPMorgan Chase & Co. , Leerink Partners , Mizuho , Needham & Company LLC , Piper Sandler , Robert W. Baird , Rothschild & Co Redburn , Royal Bank Of Canada , Sanford C. Bernstein , Stifel Nicolaus , TD Cowen , The Goldman Sachs Group , Truist Financial , UBS Group , Weiss Ratings , and Wells Fargo & Company in the past 90 days.

$79.37 +0.03 (+0.03%)

Closing price 06/18/2026 03:59 PM Eastern

Extended Trading

$79.40 +0.03 (+0.04%)

As of 06/18/2026 07:45 PM Eastern

Compare

Medtronic - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 28 Analyst Ratings

Sell
0

Hold
11

Buy
17

Based on 28 Wall Street analysts who have issued ratings for Medtronic in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 28 analysts, 11 have given a hold rating, and 17 have given a buy rating for MDT.

Consensus Price Target

$99.00
24.74% Upside

According to the 28 analysts' twelve-month price targets for Medtronic, the average price target is $99.00. The highest price target for MDT is $120.00, while the lowest price target for MDT is $78.00. The average price target represents a forecasted upside of 24.74% from the current price of $79.37.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for MDT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Medtronic and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MDT Analyst Ratings Over Time

Type	Current Forecast 6/20/25 to 6/20/26	1 Month Ago 5/21/25 to 5/21/26	3 Months Ago 3/22/25 to 3/22/26	1 Year Ago 6/20/24 to 6/20/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)	2 Strong Buy rating(s)
Buy	17 Buy rating(s)	15 Buy rating(s)	15 Buy rating(s)	7 Buy rating(s)
Hold	11 Hold rating(s)	11 Hold rating(s)	10 Hold rating(s)	8 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$99.00	$106.45	$110.74	$97.87
Forecasted Upside	24.74% Upside	36.28% Upside	28.34% Upside	13.40% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

MDT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MDT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Medtronic Stock vs. The Competition

Type	Medtronic	Medical Companies	Broader Market
Consensus Rating Score	2.61	2.29	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	24.74% Upside	688.70% Upside	15.88% Upside
News Sentiment Rating	Positive News See Recent MDT News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
6/17/2026	Needham & Company LLC 4 of 5 stars	Mike Matson 2 of 5 stars	Reiterated Rating	Buy	$101.00	+24.14%
6/16/2026	Piper Sandler 2 of 5 stars	Matt O'Brien 2 of 5 stars	Reiterated Rating	Neutral	$85.00	+4.58%
6/5/2026	Rothschild & Co Redburn 4 of 5 stars		Lower Target	Buy	$111.00 ➝ $106.00	+28.58%
6/4/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lee Hambright Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$112.00 ➝ $97.00	+17.46%
6/4/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Priya Sachdeva Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$90.00 ➝ $85.00	+8.86%
6/4/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Taylor Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Hold	$88.00	+12.70%
6/4/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joshua Jennings Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$119.00	+45.13%
6/4/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Neutral	$100.00 ➝ $86.00	+4.07%
6/4/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Newitter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Hold	$95.00 ➝ $86.00	+4.18%
6/4/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Hold	$100.00 ➝ $78.00	-5.51%
Get the Latest News and Ratings for MDT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Medtronic and its competitors with MarketBeat's FREE daily newsletter.
6/4/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Roman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$84.00 ➝ $83.00	+0.55%
6/4/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Shagun Singh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$118.00	+46.09%
6/4/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$114.00 ➝ $102.00	+30.63%
6/4/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Kratky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$117.00 ➝ $104.00	+33.19%
6/4/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Rescott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$93.00 ➝ $85.00	+8.86%
6/3/2026	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ryan Zimmerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$90.00	+15.26%
6/3/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$80.00	+2.45%
6/3/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$120.00 ➝ $100.00	+35.64%
5/21/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Hold (C+) ➝ Hold (C)
4/9/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Vijay Kumar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Outperform	$106.00	+21.39%
4/7/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joanne Wuensch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$117.00 ➝ $110.00	+27.75%
4/6/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Toung Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$125.00 ➝ $115.00	+32.76%
4/1/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$118.00 ➝ $120.00	+39.57%
2/27/2026	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$117.00 ➝ $115.00	+17.83%
1/30/2026	CICC Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Outperform
1/6/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brandon Vazquez Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
11/19/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Cecilia Furlong Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$107.00 ➝ $117.00	+16.20%
6/30/2025	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Underperform ➝ Peer Perform
8/21/2024	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Market Perform	$92.00 ➝ $94.00	+10.10%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:07 AM ET.

Should I Buy Medtronic Stock? MDT Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, June 18, 2026. Please send any questions or comments about these Medtronic pros and cons to contact@marketbeat.com.

Medtronic
Bull Case

Here are some ways that investors could benefit from investing in Medtronic plc:

The company recently reported earnings per share (EPS) of $1.55, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
Medtronic plc's revenue for the quarter reached approximately $9.81 billion, surpassing forecasts, suggesting robust demand for its medical technology products.
The firm has increased its quarterly dividend to $0.72 per share, reflecting a commitment to returning value to shareholders, with an annualized yield of about 3.6%.
With a return on equity of 14.61%, Medtronic plc demonstrates effective management and profitability, which can be attractive to investors looking for solid returns.
The current stock price is around $85, which may present a favorable entry point for investors considering the company's growth trajectory and dividend yield.

Medtronic
Bear Case

Investors should be bearish about investing in Medtronic plc for these reasons:

The net margin of 13.20% indicates that while the company is profitable, there may be concerns about cost management and competitive pressures in the medical technology sector.
Medtronic plc's EPS has decreased from $1.62 in the same quarter last year, which could signal potential challenges in maintaining growth and profitability.
With a payout ratio of 76.14%, a significant portion of earnings is being distributed as dividends, which may limit the company's ability to reinvest in growth opportunities.
Insider ownership is relatively low at 0.26%, which might raise concerns about alignment between management and shareholder interests.
Analysts project an EPS of 5.94 for the current year, which may indicate slower growth expectations compared to previous periods, potentially affecting investor sentiment.

MDT Forecast - Frequently Asked Questions

According to the research reports of 28 Wall Street equities research analysts, the average twelve-month stock price forecast for Medtronic is $99.00, with a high forecast of $120.00 and a low forecast of $78.00.

28 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medtronic in the last year. There are currently 11 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MDT shares.

According to analysts, Medtronic's stock has a predicted upside of 24.74% based on their 12-month stock forecasts.

Over the previous 90 days, Medtronic's stock had 3 upgrades and 2 downgrades by analysts.

Medtronic has been rated by research analysts at Argus, Barclays, BTIG Research, Citigroup, Deutsche Bank Aktiengesellschaft, Evercore, Jefferies Financial Group, JPMorgan Chase & Co., Leerink Partners, Mizuho, Needham & Company LLC, Piper Sandler, Robert W. Baird, Rothschild & Co Redburn, Royal Bank Of Canada, Sanford C. Bernstein, Stifel Nicolaus, TD Cowen, The Goldman Sachs Group, Truist Financial, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Medtronic more than other "medical" companies. The consensus rating for Medtronic is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how MDT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Medtronic Recommendations

This page (NYSE:MDT) was last updated on 6/20/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medtronic (MDT) Stock Forecast & Price Target